Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards

Deniz C Guven1,*, Imdat Eroglu2, Rashad Ismayilov2, Ege Ulusoydan2, Oktay H Aktepe1,*, Gulcin Telli Dizman3, Zafer Arik1, Omer Dizdar1, Serhat Unal3, Gokhan Metan3 and Neyran Kertmen1

Abstract
Introduction: It was previously demonstrated that seasonal influenza incidence was significantly decreased during the COVID-19 pandemic, possibly due to respiratory and hygiene precautions. From this point, we hypothesized that the COVID-19 precautions could lead to a decrease in nosocomial infection rates in oncology inpatient wards.

Methods: We evaluated the nosocomial infection rates in an inpatient palliative oncology ward in the first 3 months of the COVID-19 pandemic in our country and compared this rate with the same time frame of the previous year in our institution.

Results: The percentage of nosocomial infections complicating the hospitalization episodes were significantly reduced in the first 3 months of the pandemic compared to the previous year (43 vs. 55 nosocomial infection episodes; 18.6% vs. 32.2%, p = 0.002). The decrease in the nosocomial infections was consistent in the different types of infections, namely pneumonia (4.8% vs. 7.6%), urinary tract infection (5.2% vs. 7.6%), bacteremia (5.2% vs. 7%) and intraabdominal infections (2.6% vs. 3.5%). The median monthly disinfectant use was significantly increased to 98 liters (interquartile range: 82–114) in 2020 compared to 72 L (interquartile range: 36–72) in 2019 (p = 0.046).

Conclusion: The continuation of the simple and feasible hygiene and distancing measures for healthcare workers and patient relatives and adaptations for earlier discharge could be beneficial for preventing nosocomial infections in oncology wards. These measures could be implemented routinely even after the COVID-19 pandemic for patient safety, especially in settings with higher nosocomial infection rates like inpatients palliative care units.

Keywords
Cancer, COVID-19, inpatient ward, nosocomial infection, pandemic

Date received: 24 February 2021; revised: 12 August 2021; accepted: 16 August 2021

Introduction
Coronavirus disease 2019 (COVID-19) created the most significant pandemic in a century and changed the World in the last year.1 Nosocomial contamination is one of the most critical transmission routes of infection and it was suggested up to one-third of COVID-19 cases could be nosocomial.2 Patients with cancer are among the most susceptible populations affected by the COVID-19 pandemic with increased hospitalization, mechanical ventilation, and death rates,3,4 so preventing nosocomial COVID-19 contamination is paramount.
Due to prevent nosocomial COVID-19 contamination, several isolation and hygiene measures were implemented in the oncology hospitals. These measures included:5,6

- placement of warning signs for social distancing,
- the use of masks by the healthcare workers,
- implementation of triage area for the body temperature measurements and symptom questioning at the entrance of the hospital,
- increased use of telemedicine,
- restrictions of the inpatient visits,
- efforts for a shorter hospital stay, and
- hospitalization of patients with respiratory symptoms in isolated rooms.

It was previously demonstrated that seasonal influenza incidence was significantly decreased during the COVID-19 pandemic,7 possibly due to respiratory and hygiene precautions for COVID-19. From this point, we hypothesized that the COVID-19 precautions could lead to a decrease in nosocomial infection rates in oncology inpatient wards. To test this hypothesis, we evaluated the nosocomial infection rates in an inpatient palliative oncology ward in the first 3 months of the COVID-19 pandemic between 11 March 2020 and 10 June 2020 in our country8 and compared this rate with the same time frame of the previous year in our institution.

Methods

Structure of inpatient ward

The study was conducted in Hacettepe University Oncology Hospital, an ESMO designated cancer center, which was served as a clean hospital during the pandemic. The inpatient ward consisted of fifteen rooms with two beds per room. Regular patient visits were conducted twice a day by a medical oncologist for supervision and treatment planning. A medical oncology resident was present in the ward during working hours and was on-call duty during the night shifts. Internal medicine residents were present during the daytime and night shifts. Additionally, daily visits to the inpatient ward were conducted by infectious disease physicians. Three nurses and two staff from housekeeping services worked for every eight-hour shift. During the COVID-19 pandemic, all staff were regularly educated for COVID-19 and additional warning cards were placed for patients with respiratory symptoms or the suspicion of COVID-19.

Nosocomial infection definitions and statistical analysis

Nosocomial infection events were defined as the infections developed after the 48 h of hospitalization, and the infections developed in the following 72 h after discharge as suggested in the literature.9,10 All patients who were hospitalized at least for 48 h were included in the study. The patients hospitalized for imaging and one-day chemotherapy discharged on the same day of hospitalization were excluded. The types of infections such as pneumonia, urinary tract infection, intraabdominal infection, and bacteremia were identified according to the infectious disease consultation notes or follow-up records. Additionally, total hand disinfectant uses were recorded for 2 years.

The descriptive features were expressed by the medians, interquartile ranges (IQR), and percentages where ever appropriate. The baseline characteristics of patients were compared with T-test and chi-square tests. The rate of nosocomial infections during hospitalization episodes was compared with the chi-square and Fischer-exact tests. The median monthly disinfectant uses were compared with Mann-Whitney U-test. All statistical analyses were performed in SPSS 25 (IBM Inc., Armonk, NY, USA) software, and a type-I error level of 5% \((p < 0.05)\) was considered as the threshold limit for statistical significance. All the performed procedures in the present study complied with the 1964 Helsinki declaration and its later amendments. This study was approved by Hacettepe University Ethics Committee.

Results

The data of 231 patients from 2020 and 171 patients from 2019 were retrospectively evaluated. The median ages of the patients \((61\ \text{(IQR}\ 49–68)\ \text{vs.}\ 62\ \text{(IQR}\ 52–68)\ \ (p = 0.840)\) for 2020 and 2019, respectively), and median duration of hospitalization were similar for 2 years \((9\ \text{(IQR}\ 3–18)\ \text{vs.}\ 8\ \text{(IQR}\ 5–17)\ \ (p = 0.840)\) for 2020 and 2019, respectively). More female patients were hospitalized in 2020 \((50.6\%\ \text{vs.}\ 39.2\%,\ p = 0.023)\). During the first 3 months of the pandemic, six patients had COVID-19 suspicion in chest scans and 92 patients had either fever or respiratory symptoms. A total of 98 SARS-CoV-2 polymerase chain reactions (PCRs) were conducted, and results of all PCR tests were negative.

Lung cancer was the most common diagnosis \((35/171)\) in 2019, followed by the pancreas \((15/171)\) and breast cancer \((13/171)\). The primary tumor distribution was somewhat different in between 2 years, with colorectal cancer being the most frequent primary \((36/231)\) and followed by lung cancer \((35/231)\) and breast cancer \((25/231)\). The gastrointestinal (GI) tumors as a group were the most frequent primary tumor in the study population \((31.6\%\ \text{in}\ 2019\ \text{and}\ 41.1\%\ \text{in}\ 2020)\) (Figure 1). Most of the patients had advanced stage disease \((93\%\ \text{in}\ 2019\ \text{and}\ 88.3\%\ \text{in}\ 2020)\).

The percentage of nosocomial infections complicating the hospitalization episodes were significantly reduced in the first 3 months of the pandemic compared to the previous year \((43\%\ \text{vs.}\ 55\%\ \text{nosocomial infection episodes}; 18.6\%\ \text{vs.}\)
32.2%, \(p = 0.002\). The decrease in the nosocomial infections was consistent in the different types of infections, namely pneumonia (4.8% vs. 7.6%), urinary tract infection (5.2% vs. 7.6%), bacteremia (5.2% vs. 7%), and intraabdominal infections (2.6% vs. 3.5%). However, the utilization rates of carbapenems (\(p = 0.204\)), colistin (\(p = 0.104\)), vancomycin, or teicoplanin (\(p = 0.318\)) were similar between 2 years (Table 1). The rate of nosocomial infections caused by multidrug-resistant bacteria was similar between 2 years (\(p = 0.677\)) (Table 2). The median monthly disinfectant use was significantly increased to 98 L (IQR 82–114) in 2020 compared to 72 L (IQR 36–72) in 2019 (\(p = 0.046\)).

**Discussion**

Herein, we demonstrated a significant decrease in the rate of nosocomial infections in an inpatient oncology ward during the first 3 months of the pandemic. The decrease was consistent in almost all infection types. We think that the preventive measures for COVID-19, led by improved hand hygiene, could be the reason for this decrease.

Infections are among the most important causes of morbidity in patients with cancer\textsuperscript{11,12} and frequently complicates the course of hospitalization,\textsuperscript{13} as evident in our study demonstrating more than 15% nosocomial infection rate during hospitalization. Our nosocomial infection rates were somewhat higher than two recent comprehensive studies reporting lower nosocomial infection rates (6.9% and 15.5%).\textsuperscript{14,15} The possible reasons for this difference could be the exclusion of patients discharged on the same day of hospitalization and our study setting (the palliative care ward). Patients hospitalized in the palliative care wards tend to be more fragile, have frequent healthcare

---

**Table 1.** The percentage of patients with nosocomial infections or wide spectrum antibiotic usage during hospitalization in 2019 and 2020.

|                          | 2019      | 2020      | \(p\)-value |
|--------------------------|-----------|-----------|--------------|
| **Nosocomial infection** |           |           |              |
| Absent                   | 116 (67.8)| 188 (81.4)| 0.002        |
| Present                  | 55 (32.2)| 43 (18.6)|              |
| **Bacteremia**           |           |           |              |
| Absent                   | 159 (93.0)| 219 (94.8)| 0.446        |
| Present                  | 12 (7.0)| 12 (5.2)|              |
| **Diarrhea**             |           |           |              |
| Absent                   | 169 (98.8)| 229 (99.1)| > 0.99       |
| Present                  | 2 (1.2)| 2 (0.9)|              |
| **Intraabdominal infection** |       |           |              |
| Absent                   | 165 (96.5)| 225 (97.4)| 0.596        |
| **Pneumonia**            |           |           |              |
| Absent                   | 158 (92.4)| 220 (95.2)| 0.235        |
| Present                  | 13 (7.6)| 11 (4.8)|              |
| **Urinary tract infection** |           |           |              |
| Absent                   | 158 (92.4)| 219 (94.8)| 0.323        |
| Present                  | 13 (7.6)| 12 (5.2)|              |
| **Carbapenem**           |           |           |              |
| Absent                   | 142 (83.0)| 180 (77.9)| 0.204        |
| Present                  | 29 (17.0)| 51 (22.1)|              |
| **Colistin**             |           |           |              |
| Absent                   | 168 (98.2)| 220 (95.2)| 0.104        |
| Present                  | 3 (1.8)| 11 (4.8)|              |
| **Vancomycin/Teicoplanin** |         |           |              |
| Absent                   | 153 (89.5)| 199 (86.1)| 0.318        |
| Present                  | 18 (10.5)| 32 (13.9)|              |

---

**Table 2.** The isolation rate of multidrug-resistant bacteria from nosocomial infections in 2019 and 2020.

|                                | 2019 (\(n\)) | 2020 (\(n\)) |
|--------------------------------|--------------|--------------|
| Methicillin-resistant *Staphylococcus epidermidis* (MRSE) | 2 | 0 |
| Methicillin-resistant *Staphylococcus aureus* (MRSA) | 0 | 2 |
| Extended-spectrum beta-lactamase-producing *Escherichia coli* or Klebsiella species | 12 | 12 |
| Carbapenem resistant *Klebsiella pneumoniae* | 1 | 1 |
| *Stenotrophomonas maltophilia* | 1 | 0 |
Contact, and have recurrent hospitalizations, which makes them vulnerable to nosocomial infections.¹⁶,¹⁷

International Societies recommend several precautions and infection control measures, and the hospital infection control units implement these recommendations to control nosocomial infections.¹² Hand hygiene is one of the most important nosocomial infection prevention interventions,¹⁸ although the compliance rates are very variable and generally far below the desired rates.¹⁹,²⁰ However, compliance to hand hygiene is expected to be improved due to the significant emphasis on this issue in the media and regular COVID-19 education emphasizing the hand hygiene during the pandemic in most institutions. Similarly, hand sanitizer uses are expected to increase during the COVID-19 pandemic as seen in our experience. All these factors could lead to optimized hand hygiene during the pandemic and could be the main reason for the decreased nosocomial infection rates in our study. Although we could not be able to evaluate the difference due to no PCR-confirmed influenza cases during our study frame in both years, social distancing, use of masks and the prompt respiratory isolation could lead to decreased rates of nosocomial influenza and other respiratory virus contaminations.

Our study has several limitations. The study was a single-center retrospective study, including a modest number of cases. Our institution served as a clean hospital during the pandemic, which impairs the generalizability of our results to centers that are overwhelmed by a high number of cases. However, the clean hospital setting could be a better reflector of the precautions’ efficacy without the confounding of nosocomial COVID-19 contamination. Additionally, we categorized the types of infections based on infectious diseases consultations rather than the Center for Disease Control and Prevention criteria which is commonly used in the epidemiological investigations. Lastly, our study was conducted during a period of strict precautions but no lockdown. This limits our results’ generalizability to countries that did not adopt strict measures like Sweden and countries that applied a nationwide lockdown like New Zealand during the pandemic. Despite these limitations, we could give a general perspective about the off-target benefits of hygiene precautions for COVID-19 on nosocomial infections.

In conclusion, we observed a significant decrease in the nosocomial infection rates during the COVID-19 pandemic in our institution. The continuation of the simple and feasible hygiene and distancing measures for healthcare workers and patient relatives and adaptations for earlier discharge could be beneficial for preventing nosocomial infections in oncology wards. These measures could be implemented routinely even after the COVID-19 pandemic for patient safety, especially in settings with higher nosocomial infection rates like inpatient palliative care units.

**Compliance with ethical standards**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of Hacettepe University and the Turkish Ministry of Health.

**Declaration of Conflicting Interests**

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The authors received no financial support for the research, authorship, and/or publication of this article.

**ORCID iDs**

Deniz C Guven https://orcid.org/0000-0002-6924-9467

Oktay H Aktepe https://orcid.org/0000-0003-3540-0701

**References**

1. Morens DM and Fauci AS. Emerging pandemic diseases: how we got to COVID-19. *Cell* 2020; 182: 1077–1092.

2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. *JAMA* 2020; 323: 1061.

3. Saini KS, Tagliamento M, Lambertini M, et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. *Eur J Cancer* 2020; 139: 43–50.

4. Lee LYW, Cazier J-B, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. *Lancet Oncol* 2020; 21: 1309–1316.

5. Guven DC, Aktas BY, Aksun MS, et al. COVID-19 pandemic: changes in cancer admissions. *BMJ Support Palliat Care* 2020; bmjspcare-2020-002468. doi: 10.1136/bmjspcare-2020-002468.

6. Karacin C, Acar R, Bal O, et al. “Swords and shields” against COVID-19 for patients with cancer at “clean” and “pandemic” hospitals: are we ready for the second wave? *Support Care Cancer* 2021; 29: 4587–4593.

7. Olsen SJ, Azziz-Baumgartner E, Budd AP, et al. Decreased influenza activity during the COVID-19 pandemic—United States, Australia, Chile, and South Africa, 2020. *MMWR Morbidity and Mortality Weekly Report* 2020; 69: 1305–1309.

8. Koca F. Promotion of scientific research on COVID-19 in Turkey. *Lancet* 2020; 396: e25–e26.

9. Inweregbu K, Dave J and Pittard A. Nosocomial infections. *Continuing Education in Anaesthesia Critical Care & Pain* 2005; 5: 14–17.

10. Revelas A. Healthcare-associated infections: a public health problem. *Niger Med J* 2012 Apr; 53: 59–64. PMID: 23271847; PMCID: PMC3530249.
11. Rolston KVI. Infections in cancer patients with solid tumors: a review. Infect Dis Ther 2017; 6: 69–83.
12. Kamboj M and Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol 2009; 10: 589–597.
13. Valentine JC, Hall L, Spelman T, et al. Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre. Support Care Cancer 2020; 28: 6023–6034.
14. Liu H, Zhao J, Xing Y, et al. Nosocomial infection in adult admissions with hematological malignancies originating from different lineages: a prospective observational study. PLOS One 2014; 9, e113506.
15. Jiang A-M, Shi X, Liu N, et al. Nosocomial infections due to multidrug-resistant bacteria in cancer patients: a six-year retrospective study of an oncology center in western China. BMC Infect Dis 2020; 20: 452.
16. Thai V, Lau F, Wolch G, et al. Impact of infections on the survival of hospitalized advanced cancer patients. J Pain Symptom Manage 2012; 43: 549–557.
17. Guven DC, Ceylan F, Cakir IY, et al. Evaluation of early unplanned readmissions and predisposing factors in an oncology clinic. Support Care Cancer 2021; 29: 4159–4164.
18. Boyce JM and Pittet D. Healthcare Infection Control Practices Advisory Committee, HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for Hand Hygiene in Health Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR. Recommendations and Reports: Morbidity and Mortality Weekly report. Recommendations and Reports. 2002 Oct;51(RR-16):1-45, quiz CE1-4.
19. Lambe KA, Lydon S, Madden C, et al. Hand hygiene compliance in the ICU. Crit Care Med 2019; 47: 1251–1257.
20. Zottele C, Magnano TSBDS, Dullius AIDS, et al. Hand hygiene compliance of healthcare professionals in an emergency department. Rev Esc Enferm USP 2017; 51: e03242. DOI: 10.1590/s1980-220×2016027303242. Epub ahead of print.